Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis

Highlights • Most of CVD comorbidities were associated with decreased survival of NSCLC patients. • The impact of CVD comorbidities varies by lung cancer stage and treatment. • The large population-based dataset of older U.S. adults is used in analysis. • The results help choose lung cancer treatmen...

Full description

Saved in:
Bibliographic Details
Published inLung cancer (Amsterdam, Netherlands) Vol. 88; no. 1; pp. 85 - 93
Main Authors Kravchenko, Julia, Berry, Mark, Arbeev, Konstantin, Kim Lyerly, H, Yashin, Anatoly, Akushevich, Igor
Format Journal Article
LanguageEnglish
Published Ireland 01.04.2015
Subjects
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung - mortality
Cardiovascular Diseases - mortality
Comorbidity
Female
Hematology, Oncology and Palliative Medicine
Humans
Lung Neoplasms - mortality
Lung Neoplasms - therapy
Male
Medicare
Proportional Hazards Models
Pulmonary/Respiratory
Retrospective Studies
United States
United States
Cancer stage
Cardiovascular disease
Comorbidity
Cancer treatment
Survival
Lung cancer
Online AccessGet full text

Cover

More Information
Summary:Highlights • Most of CVD comorbidities were associated with decreased survival of NSCLC patients. • The impact of CVD comorbidities varies by lung cancer stage and treatment. • The large population-based dataset of older U.S. adults is used in analysis. • The results help choose lung cancer treatment in older patients with comorbidities.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2015.01.006